First do no harm: Promoting an evidence-based approach to atypical antipsychotic use in children and adolescents

Journal of the Canadian Academy of Child and Adolescent Psychiatry

Volumn 19, Issue 2, 2010, Pages 124-137

  Panagiotopoulos, Constadina ^a   Ronsley, Rebecca ^a   Elbe, Dean ^b   Davidson, Jana ^a,c   Smith, Derryck H ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b British Columbia Research Institute for Children's and Women's Health   (United States)

^c BC CHILDREN S HOSPITAL   (Canada)

Author keywords

Adolescents; Atypical antipsychotics; Children; Efficacy; Metabolic; Monitoring

Indexed keywords

AMINOTRANSFERASE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; HALOPERIDOL; OLANZAPINE; PROLACTIN; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADOLESCENT; ALGORITHM; ANTHROPOMETRIC PARAMETERS; ATTENTION DEFICIT DISORDER; AUTISM; BIPOLAR DISORDER; BIPOLAR I DISORDER; CANADA; CHILD; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONDUCT DISORDER; DEVELOPMENTAL DISORDER; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DISRUPTIVE BEHAVIOR; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG METABOLISM; DRUG MONITORING; DRUG USE; DYSLIPIDEMIA; EVIDENCE BASED PRACTICE; FOOD AND DRUG ADMINISTRATION; GILLES DE LA TOURETTE SYNDROME; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INFORMATION RETRIEVAL; LABORATORY TEST; MEDLINE; METABOLIC SYNDROME X; PRACTICE GUIDELINE; PROLACTIN BLOOD LEVEL; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; UNITED STATES; WAIST CIRCUMFERENCE; WEIGHT GAIN;

EID: 77951703552     PISSN: 17198429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (122)

1. Addington, A. M., & Rapoport, J. L. (2009). The genetics of childhood-onset schizophrenia: When madness strikes the prepubescent. Current Psychiatry Reports, 11(2), 156-161.
2. Alfaro, C. L., Wudarsky, M., Nicolson, R., Gochman, P., Sporn, A., Lenane, M., et al. (2002). Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine. Journal of Child and Adolescent Psychopharmacology, 12(2), 83-91.
3. Aman, M. G., Hollway J. A., Leone, S., Masty, J., Lindsay, R., Nash, P., et al. (2009). Effects of Risperidone on cognitive-motor performance and motor movements in chronically medicated children. Research in Developmental Disabilities, 30, 386-396.
4. Aman, M. G., Hollway, J. A., McDougle, C. J., Scahill, L., Tierney, E., McCracken, J. T., et al. (2008). Cognitive effects of risperidone in children with autism and irritable behavior. Journal of Child and Adolescent Psychopharmacology, 18(3), 227-236.
5. Aman, M. G., Arnold, L. E., McDougle, C. J., Vitiello, B., Scahill, L., Davies, M., et al. (2005). Acute and long-term safety and tolerability of risperidone in children with autism. Journal of Child and Adolescent Psychopharmacology, 15(6), 869-884.
6. Aman, M. G., Binder, C., & Turgay, A. (2004). Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ. Journal of Child and Adolescent Psychopharmacology, 14(2), 243-254.
7. Aman, M. G., De Smedt, G., Derivan, A., Lyons, B., Findling, R. L., & Risperidone Disruptive Behavior Study Group (2002). Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. The American Journal of Psychiatry, 159(8), 1337-1346.
8. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, & North American Association for the Study of Obesity (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care, 27(2), 596-601.
9. Anderson, G. M., Scahill, L., McCracken, J. T., McDougle, C. J., Aman, M. G., Tierney, E., et al. (2007). Effects of shortand long-term risperidone treatment on prolactin levels in children with autism. Biological Psychiatry, 61(4), 545-550.
10. Arango, C., Robles, O., Parellada, M., Fraguas, D., Ruiz-Sancho, A., Medina, O., et al. (2009). Olanzapine compared to quetiapine in adolescents with a first psychotic episode. European Child & Adolescent Psychiatry, 18(7), 418-428.
11. Armenteros, J. L., Lewis, J. E., & Davalos, M. (2007). Risperidone augmentation for treatment-resistant aggression in attention-deficit/hyperactivity disorder: A placebocontrolled pilot study. Journal of the American Academy of Child and Adolescent Psychiatry, 46(5), 558-565.
12. Berenson, G. S., Srinivasan, S. R., Bao, W., Newman, W. P., 3rd, Tracy, R. E., & Wattigney, W. A. (1998). Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. the bogalusa heart study. The New England Journal of Medicine, 338(23), 1650-1656.
13. Biederman, J., Mick, E., Faraone, S. V., Wozniak, J., Spencer, T., & Pandina, G. (2006). Risperidone for the treatment of affective symptoms in children with disruptive behavior disorder: A post hoc analysis of data from a 6-week, multicenter, randomized, double-blind, parallel-arm study. Clinical Therapeutics, 28(5), 794-800.
14. Bitsori, M., Linardakis, M., Tabakaki, M., & Kafatos, A. (2009). Waist circumference as a screening tool for the identification of adolescents with the metabolic syndrome phenotype. International Journal of Pediatric Obesity: IJPO: An Official Journal of the International Association for the Study of Obesity, 4(4), 325-331.
15. Bruggeman, R., van der Linden, C., Buitelaar, J. K., Gericke, G. S., Hawkridge, S. M., & Temlett, J. A. (2001). Risperidone versus pimozide in tourette's disorder: A comparative double-blind parallel-group study. The Journal of Clinical Psychiatry, 62(1), 50-56.
16. Buitelaar, J. K., van der Gaag, R. J., Cohen-Kettenis, P., & Melman, C. T. (2001). A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. Journal of Clinical Psychiatry, 62(4), 239-248.
17. Cache Limited (2010). Oxford centre for evidence-based medicine levels of evidence. Retrieved 11/23, 2009, from http://www.cebm.net/index.aspx?o=1025.
18. Calarge, C. A., Acion, L., Kuperman, S., Tansey, M., & Schlechte, J. A. (2009). Weight gain and metabolic abnormalities during extended risperidone treatment in children and adolescents. Journal of Child and Adolescent Psychopharmacology, 19(2), 101-109.
19. Center for Disease Control and Prevention (2007). CDC growth charts United States 2000.
20. Chintoh, A. F., Mann, S. W., Lam, L., Lam, C., Cohn, T. A., Fletcher, P. J., et al. (2008). Insulin resistance and decreased glucose-stimulated insulin secretion after acute olanzapine administration. Journal of Clinical Psychopharmacology, 28(5), 494-499.
21. Cohen, D. (2004). Atypical antipsychotics and new onset diabetes mellitus. An overview of the literature. Pharmacopsychiatry, 37(1), 1-11.
22. Connor, D. F., McLaughlin, T. J., & Jeffers-Terry, M. (2008). Randomized controlled pilot study of quetiapine in the treatment of adolescent conduct disorder. Journal of Child and Adolescent Psychopharmacology, 18(2), 140-156.
23. Cooper, W. O., Arbogast, P. G., Ding, H., Hickson, G. B., Fuchs, D. C., & Ray, W. A. (2006). Trends in prescribing of antipsychotic medications for US children. Ambulatory Pediatrics: The Official Journal of the Ambulatory Pediatric Association, 6(2), 79-83.
24. Correia Filho, A. G., Bodanese, R., Silva, T. L., Alvares, J. P., Aman, M., & Rohde, L. A. (2005). Comparison of risperidone and methylphenidate for reducing ADHD symptoms in children and adolescents with moderate mental retardation. Journal of the American Academy of Child and Adolescent Psychiatry, 44(8), 748-755.
25. Correll, C. U., Manu, P., Olshanskiy, V., Napolitano, B., Kane, J. M., & Malhotra, A. K. (2009). Cardiometabolic risk of second-generation antipsychotic medications during firsttime use in children and adolescents. The Journal of the American Medical Association, 302(16), 1765-1773.
26. Correll, C. U. (2009). Multiple antipsychotic use associated with metabolic and cardiovascular adverse events in children and adolescents. Evidence-Based Mental Health, 12(3), 93.
27. Correll, C. U., & Carlson, H. E. (2006). Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry, 45(7), 771-791.
28. Correll, C. U., Leucht, S., & Kane, J. M. (2004). Lower risk for tardive dyskinesia associated with second-generation antipsychotics: A systematic review of 1-year studies. The American Journal of Psychiatry, 161(3), 414-425.
29. DelBello, M. P., Chang, K., Welge, J. A., Adler, C. M., Rana, M., Howe, M., et al. (2009). A double-blind, placebo-controlled pilot study of quetiapine for depressed adolescents with bipolar disorder. Bipolar Disorders, 11(5), 483-493.
30. Delbello, M., Findling, R., Wang, P., Gundapeneni, B., &Versavel, M. (2008). Poster: Efficacy and safety of ziprasidone in pediatric bipolar disorder. Unpublished manuscript.
31. DelBello, M. P., Kowatch, R. A., Adler, C. M., Stanford, K. E., Welge, J. A., Barzman, D. H., et al. (2006). A double-blind randomized pilot study comparing quetiapine and divalproex for adolescent mania. Journal of the American Academy of Child and Adolescent Psychiatry, 45(3), 305-313.
32. Delbello, M. P., Schwiers, M. L., Rosenberg, H. L., & Strakowski, S. M. (2002). A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. Journal of the American Academy of Child and Adolescent Psychiatry, 41(10), 1216-1223.
33. Dittmann, R. W., Meyer, E., Freisleder, F. J., Remschmidt, H., Mehler-Wex, C., Junghanss, J., et al. (2008). Effectiveness and tolerability of olanzapine in the treatment of adolescents with schizophrenia and related psychotic disorders: Results from a large, prospective, open-label study. Journal of Child and Adolescent Psychopharmacology, 18(1), 54-69.
34. Doey, T., Handelman, K., Seabrook, J. A., & Steele, M. (2007). Survey of atypical antipsychotic prescribing by Canadian child psychiatrists and developmental pediatricians for patients under 18 years of age. Canadian Journal of Psychiatry, 52(6), 363-368.
35. Domino, M. E., & Swartz, M. S. (2008). Who are the new users of antipsychotic medications? Psychiatric Services, 59(5), 507-514.
36. Erdogan, A., Atasoy, N., Akkurt, H., Ozturk, D., Karaahmet, E., Yalug, I., et al. (2008). Risperidone and liver function tests in children and adolescents: A short-term prospective study. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 32(3), 849-857.
37. Feret, B. M., & Caley, C. F. (2000). Possible hypothyroidism associated with quetiapine. The Annals of Pharmacotherapy, 34(4), 483-486.
38. Findling, R. L., Nyilas, M., Forbes, R. A., McQuade, R. D., Jin, N., Iwamoto, T., et al. (2009). Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: A randomized, double-blind, placebo-controlled study. The Journal of Clinical Psychiatry, 70(10), 1441-1451.
39. Findling, R. L., Robb, A., Nyilas, M., Forbes, R. A., Jin, N., Ivanova, S., et al. (2008). A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. The American Journal of Psychiatry, 165(11), 1432-1441.
40. Findling, R. L., Aman, M. G., Eerdekens, M., Derivan, A., Lyons, B., & Risperidone Disruptive Behavior Study Group (2004). Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQ. The American Journal of Psychiatry, 161(4), 677-684.
41. Findling, R. L., Kusumakar, V., Daneman, D., Moshang, T., De Smedt, G., & Binder, C. (2003). Prolactin levels during longterm risperidone treatment in children and adolescents. The Journal of Clinical Psychiatry, 64(11), 1362-1369.
42. Fleischhaker, C., Heiser, P., Hennighausen, K., Herpertz-Dahlmann, B., Holtkamp, K., Mehler-Wex, C., et al. (2007). Weight gain associated with clozapine, olanzapine and risperidone in children and adolescents. Journal of Neural Transmission, 114(2), 273-280.
43. Food and Drug Administration (2010). Atypical antipsychotic drugs information. Retrieved 11/23, 2009, from http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm094303.htm
44. Fraguas, D., Merchan-Naranjo, J., Laita, P., Parellada, M., Moreno, D., Ruiz-Sancho, A., et al. (2008). Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics. The Journal of Clinical Psychiatry, 69(7), 1166-1175.
45. Gaffney, G. R., Perry, P. J., Lund, B. C., Bever-Stille, K. A., Arndt, S., & Kuperman, S. (2002). Risperidone versus clonidine in the treatment of children and adolescents with tourette's syndrome. Journal of the American Academy of Child and Adolescent Psychiatry, 41(3), 330-336.
46. Geller, B., Tillman, R., & Bolhofner, K. (2007). Proposed definitions of bipolar I disorder episodes and daily rapid cycling phenomena in preschoolers, school-aged children, adolescents, and adults. Journal of Child and Adolescent Psychopharmacology, 17(2), 217-222.
47. Gilbert, D. L., Batterson, J. R., Sethuraman, G., & Sallee, F. R. (2004). Tic reduction with risperidone versus pimozide in a randomized, double-blind, crossover trial. Journal of the American Academy of Child and Adolescent Psychiatry, 43(2), 206-214.
48. Gitlin, N., Julie, N. L., Spurr, C. L., Lim, K. N., & Juarbe, H. M. (1998). Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone. Annals of Internal Medicine, 129(1), 36-38.
49. Gonzalez-Heydrich, J., Raches, D., Wilens, T. E., Leichtner, A., & Mezzacappa, E. (2003). Retrospective study of hepatic enzyme elevations in children treated with olanzapine, divalproex, and their combination. Journal of the American Academy of Child and Adolescent Psychiatry, 42(10), 1227-1233.
50. Gropper, D., & Jackson, C. W. (2004). Pancreatitis associated with quetiapine use. Journal of Clinical Psychopharmacology, 24(3), 343-345.
51. Haas, M., Eerdekens, M., Kushner, S., Singer, J., Augustyns, I., Quiroz, J., et al. (2009). Efficacy, safety and tolerability of two dosing regimens in adolescent schizophrenia: Doubleblind study. The British Journal of Psychiatry: The Journal of Mental Science, 194(2), 158-164.
52. Harrison-Woolrych, M., Garcia-Quiroga, J., Ashton, J., & Herbison, P. (2007). Safety and usage of atypical antipsychotic medicines in children: A nationwide prospective cohort study. Drug Safety: An International Journal of Medical Toxicology and Drug Experience, 30(7), 569-579.
53. Haupt, D. W., Rosenblatt, L. C., Kim, E., Baker, R. A., Whitehead, R., & Newcomer, J. W. (2009). Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents. The American Journal of Psychiatry, 166(3), 345-353.
54. Health Canada (2009). Drug product search. Retrieved 02/02, 2010, from http://webprod.hc-sc.gc.ca/dpd-bdpp/indexeng.jsp
55. Henderson, D. C. (2002). Atypical antipsychotic-induced diabetes mellitus: How strong is the evidence? CNS Drugs, 16(2), 77-89.
56. Hermann, R. C., Yang, D., Ettner, S. L., Marcus, S. C., Yoon, C., & Abraham, M. (2002). Prescription of antipsychotic drugs by office-based physicians in the United States, 1989-1997. Psychiatric Services, 53(4), 425-430.
57. Hollander, E., Wasserman, S., Swanson, E. N., Chaplin, W., Schapiro, M. L., Zagursky, K., et al. (2006). A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. Journal of Child and Adolescent Psychopharmacology, 16(5), 541-548.
58. Kane, J. M. (2001). Extrapyramidal side effects are unacceptable. European Neuropsychopharmacology, 11 Suppl 4, S397-403.
59. Kelly, D. L., & Conley, R. R. (2005). Thyroid function in treatment-resistant schizophrenia patients treated with quetiapine, risperidone, or fluphenazine. The Journal of Clinical Psychiatry, 66(1), 80-84.
60. Kohlroser, J., Mathai, J., Reichheld, J., Banner, B. F., & Bonkovsky, H. L. (2000). Hepatotoxicity due to troglitazone: Report of two cases and review of adverse events reported to the United States food and drug administration. The American Journal of Gastroenterology, 95(1), 272-276.
61. Koller, E. A., Weber, J., Doraiswamy, P. M., & Schneider, B. S. (2004). A survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus. The Journal of Clinical Psychiatry, 65(6), 857-863.
62. Koller, E. A., Cross, J. T., & Schneider, B. (2004). Risperidoneassociated diabetes mellitus in children. Pediatrics, 113(2), 421-2; author reply 421-2.
63. Koller, E., Malozowski, S., & Doraiswamy, P. M. (2001). Atypical antipsychotic drugs and hyperglycemia in adolescents. The Journal of the American Medical Association, 286(20), 2547-2548.
64. Kryzhanovskaya, L., Schulz, S. C., McDougle, C., Frazier, J., Dittmann, R., Robertson-Plouch, C., et al. (2009). Olanzapine versus placebo in adolescents with schizophrenia: A 6-week, randomized, double-blind, placebo-controlled trial. Journal of the American Academy of Child and Adolescent Psychiatry, 48(1), 60-70.
65. Kumra, S., Herion, D., Jacobsen, L. K., Briguglia, C., & Grothe, D. (1997). Case study: Risperidone-induced hepatotoxicity in pediatric patients. Journal of the American Academy of Child and Adolescent Psychiatry, 36(5), 701-705.
66. Laita, P., Cifuentes, A., Doll, A., Llorente, C., Cortes, I., Parellada, M., et al. (2007). Antipsychotic-related abnormal involuntary movements and metabolic and endocrine side effects in children and adolescents. Journal of Child and Adolescent Psychopharmacology, 17(4), 487-502.
67. Li, S., Chen, W., Srinivasan, S. R., Bond, M. G., Tang, R., Urbina, E. M., et al. (2003). Childhood cardiovascular risk factors and carotid vascular changes in adulthood: The Bogalusa heart study. The Journal of the American Medical Association, 290(17), 2271-2276.
68. Madhusoodanan, S., & Moise, D. (2006). Risperidone-induced hyperprolactinemia in adolescents: A case series. The Journal of Clinical Psychiatry, 67(7), 1110-1113.
69. Malik, A. H., Prasad, P., Saboorian, M. H., Thiele, D. L., & Malet, P. F. (2000). Hepatic injury due to troglitazone. Digestive Diseases and Sciences, 45(1), 210-214.
70. Marcus, R. N., Owen, R., Kamen, L., Manos, G., McQuade, R. D., Carson, W. H., et al. (2009). A placebo-controlled, fixeddose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 48(11), 1110-1119.
71. Martin, A., Scahill, L., Anderson, G. M., Aman, M., Arnold, L. E., McCracken, J., et al. (2004). Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data. The American Journal of Psychiatry, 161(6), 1125-1127.
72. Martin, A., & L'Ecuyer, S. (2002). Triglyceride, cholesterol and weight changes among risperidone-treated youths. A retrospective study. European Child & Adolescent Psychiatry, 11(3), 129-133.
73. Martin, A., Landau, J., Leebens, P., Ulizio, K., Cicchetti, D., Scahill, L., et al. (2000). Risperidone-associated weight gain in children and adolescents: A retrospective chart review. Journal of Child and Adolescent Psychopharmacology, 10(4), 259-268.
74. Masi, G., Cosenza, A., & Mucci, M. (2001). Prolactin levels in young children with pervasive developmental disorders during risperidone treatment. Journal of Child and Adolescent Psychopharmacology, 11(4), 389-394.
75. McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., et al. (2002). Risperidone in children with autism and serious behavioral problems. The New England Journal of Medicine, 347(5), 314-321.
76. McDougle, C. J., Scahill, L., Aman, M. G., McCracken, J. T., Tierney, E., Davies, M., et al. (2005). Risperidone for the core symptom domains of autism: Results from the study by the autism network of the research units on pediatric psychopharmacology. The American Journal of Psychiatry, 162(6), 1142-1148.
77. McIntyre, R. S., & Jerrell, J. M. (2008). Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents. Archives of Pediatrics & Adolescent Medicine, 162(10), 929-935.
78. Melkersson, K., & Dahl, M. L. (2004). Adverse metabolic effects associated with atypical antipsychotics: Literature review and clinical implications. Drugs, 64(7), 701-723.
79. Meyer, J., Koro, C. E., & L'Italien, G. J. (2005). The metabolic syndrome and schizophrenia: A review. International Review of Psychiatry, 17(3), 173-180.
80. Meyer, J. M., & Koro, C. E. (2004). The effects of antipsychotic therapy on serum lipids: A comprehensive review. Schizophrenia Research, 70(1), 1-17.
81. Miral, S., Gencer, O., Inal-Emiroglu, F. N., Baykara, B., Baykara, A., & Dirik, E. (2008). Risperidone versus haloperidol in children and adolescents with AD: A randomized, controlled, double-blind trial. European Child & Adolescent Psychiatry, 17(1), 1-8.
82. Mond, J., Morice, R., Owen, C., & Korten, A. (2003). Use of antipsychotic medications in Australia between July 1995 and December 2001. The Australian and New Zealand Journal of Psychiatry, 37(1), 55-61.
83. Morrato, E. H., Newcomer, J. W., Kamat, S., Baser, O., Harnett, J., & Cuffel, B. (2009). Metabolic screening after the American Diabetes Association's consensus statement on antipsychotic drugs and diabetes. Diabetes Care, 32(6), 1037-1042.
84. Nagaraj, R., Singhi, P., & Malhi, P. (2006). Risperidone in children with autism: Randomized, placebo-controlled, doubleblind study. Journal of Child Neurology, 21(6), 450-455.
85. Nasrallah, H. A., & Newcomer, J. W. (2004). Atypical antipsychotics and metabolic dysregulation: Evaluating the risk/benefit equation and improving the standard of care. Journal of Clinical Psychopharmacology, 24(5 Suppl 1), S7-14.
86. Newcomer, J. W. (2005). Second-generation (atypical) antipsychotics and metabolic effects: A comprehensive literature review. CNS Drugs, 19, S1-S93.
87. Olfson, M., Blanco, C., Liu, L., Moreno, C., & Laje, G. (2006). National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Archives of General Psychiatry, 63(6), 679-685.
88. Owen, R., Sikich, L., Marcus, R. N., Corey-Lisle, P., Manos, G., McQuade, R. D., et al. (2009). Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics, 124(6), 1533-1540.
89. Panagiotopoulos, C., Davidson, J., & Weiss, M. (2009). Treatment with atypical antipsychotics increases the risk for metabolic syndrome in youth with mental illness. Poster Presentation at the Annual Meeting of the American Academy of Child & Adolescent Psychiatry (AACAP), October 27-November 1 2009.
90. Panagiotopoulos, C., Ronsley, R., & Davidson, J. (2009). Increased prevalence of obesity and glucose intolerance in youth treated with second-generation antipsychotic medications. Canadian Journal of Psychiatry, 54(11), 743-749.
91. Pandina, G. J., Bossie, C. A., Youssef, E., Zhu, Y., & Dunbar, F. (2007). Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebocontrolled trial. Journal of Autism and Developmental Disorders, 37(2), 367-373.
92. Patel, N. C., Hariparsad, M., Matias-Akthar, M., Sorter, M. T., Barzman, D. H., Morrison, J. A., et al. (2007). Body mass indexes and lipid profiles in hospitalized children and adolescents exposed to atypical antipsychotics. Journal of Child and Adolescent Psychopharmacology, 17(3), 303-311.
93. Patel, N. C., Kistler, J. S., James, E. B., & Crismon, M. L. (2004). A retrospective analysis of the short-term effects of olanzapine and quetiapine on weight and body mass index in children and adolescents. Pharmacotherapy, 24(7), 824-830.
94. Penzner, J. B., Dudas, M., Saito, E., Olshanskiy, V., Parikh, U. H., Kapoor, S., et al. (2009). Lack of effect of stimulant combination with second-generation antipsychotics on weight gain, metabolic changes, prolactin levels, and sedation in youth with clinically relevant aggression or oppositionality. Journal of Child and Adolescent Psychopharmacology, 19(5), 563-573.
95. Pharmacare (2009). Policy, outcomes evaluation and research, Pharmaceutical Services Division, Ministry of Health Services. Unpublished manuscript.
96. Raitakari, O. T., Juonala, M., Kahonen, M., Taittonen, L., Laitinen, T., Maki-Torkko, N., et al. (2003). Cardiovascular risk factors in childhood and carotid artery intima-media thickness in adulthood: The cardiovascular risk in young Finns study. The Journal of the American Medical Association, 290(17), 2277-2283.
97. Ratzoni, G., Gothelf, D., Brand-Gothelf, A., Reidman, J., Kikinzon, L., Gal, G., et al. (2002). Weight gain associated with olanzapine and risperidone in adolescent patients: A comparative prospective study. Journal of the American Academy of Child and Adolescent Psychiatry, 41(3), 337-343.
98. Reyes, M., Buitelaar, J., Toren, P., Augustyns, I., & Eerdekens, M. (2006). A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. American Journal of Psychiatry, 163(3), 402-410.
99. Salle, F., Kurlan, R., Goetz, C., Singer, H., Scahill, L., Law, G., et al. (2000). Ziprasidone treatment of children and adolescents with tourette's syndrome: A pilot study. Journal of the American Academy of Child and Adolescent Psychiatry, 39(3), pages.
100. Savoy, Y. E., Ashton, M. A., Miller, M. W., Nedza, F. M., Spracklin, D. K., Hawthorn, M. H., et al. (2008). Differential effects of various typical and atypical antipsychotics on plasma glucose and insulin levels in the mouse: Evidence for the involvement of sympathetic regulation. Schizophrenia Bulletin, 36(2), 410-418.
101. Scahill, L., Leckman, J. F., Schultz, R. T., Katsovich, L., & Peterson, B. S. (2003). A placebo-controlled trial of risperidone in tourette syndrome. Neurology, 60(7), 1130-1135.
102. Shea, S., Turgay, A., Carroll, A., Schulz, M., Orlik, H., Smith, I., et al. (2004). Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics, 114(5), e634-41.
103. Shirzadi, A. A., & Ghaemi, S. N. (2006). Side effects of atypical antipsychotics: Extrapyramidal symptoms and the metabolic syndrome. Harvard Review of Psychiatry, 14(3), 152-164.
104. Sikich, L., Frazier, J. A., McClellan, J., Findling, R. L., Vitiello, B., Ritz, L., et al. (2008). Double-blind comparison of firstand second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: Findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. The American Journal of Psychiatry, 165(11), 1420-1431.
105. Snyder, R., Turgay, A., Aman, M., Binder, C., Fisman, S., Carroll, A., et al. (2002). Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. Journal of the American Academy of Child and Adolescent Psychiatry, 41(9), 1026-1036.
106. Sporn, A. L., Vermani, A., Greenstein, D. K., Bobb, A. J., Spencer, E. P., Clasen, L. S., et al. (2007). Clozapine treatment of childhood-onset schizophrenia: Evaluation of effectiveness, adverse effects, and long-term outcome. Journal of the American Academy of Child and Adolescent Psychiatry, 46(10), 1349-1356.
107. Szigethy, E., Wiznitzer, M., Branicky, L. A., Maxwell, K., & Findling, R. L. (1999). Risperidone-induced hepatotoxicity in children and adolescents? A chart review study. Journal of Child and Adolescent Psychopharmacology, 9(2), 93-98.
108. Tandon, R., & Halbreich, U. (2003). The second-generation 'atypical' antipsychotics: Similar improved efficacy but different neuroendocrine side effects. Psychoneuroendocrinology, 28(suppl 1), 1-7.
109. Therapeutics initiative (2009). Increasing use of newer antipsychotics in children: A cause for concern? Therapeutics Initiative: Evidence Based Drug Therapy, April-June 2009.
110. Tohen, M., Kryzhanovskaya, L., Carlson, G., Delbello, M., Wozniak, J., Kowatch, R., et al. (2007). Olanzapine versus placebo in the treatment of adolescents with bipolar mania. The American Journal of Psychiatry, 164(10), 1547-1556.
111. Tramontina, S., Zeni, C. P., Ketzer, C. R., Pheula, G. F., Narvaez, J., & Rohde, L. A. (2009). Aripiprazole in children and adolescents with bipolar disorder comorbid with attentiondeficit/hyperactivity disorder: A pilot randomized clinical trial. The Journal of Clinical Psychiatry, 70(5), 756-764.
112. Turgay, A., Binder, C., Snyder, R., & Fisman, S. (2002). Longterm safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. Pediatrics, 110(3), e34.
113. US Food and Drug Administration (2010). Zyprexa (olanzapine): Use in adolescents. Retrieved 02/02, 2010, from http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm198402.htm
114. Walter, G., DeLaroche, A., Soh, N., Hunt, G., Cleary, M., Malhi, G., et al. (2008). Side effects of second-generation antipsychotics: The experiences, views and monitoring practices of Australian child psychiatrists. Australasian Psychiatry, 16(4), 253-262.
115. Weiss, M., Panagiotopoulos, C., Giles, L., Gibbins, C., Kuzeljevic, B., Davidson, J., et al. (2009). A naturalistic study of predictors and risks of atypical antipsychotic use in an attentiondeficit/hyperactivity disorder clinic. Journal of Child and Adolescent Psychopharmacology, 19(5), 575-582.
116. Weiss, R., Dziura, J., Burgert, T. S., Tamborlane, W. V., Taksali, S. E., Yeckel, C. W., et al. (2004). Obesity and the metabolic syndrome in children and adolescents. The New England Journal of Medicine, 350(23), 2362-2374.
117. Woo, V., Harris, S., & Houlden, R. (2005). Canadian diabetes association position paper: Antipsychotic medications and associated risks of weight gain and diabetes. Canadian Journal of Diabetes, 29(2), 111.
118. Woods, S. W., Martin, A., Spector, S. G., & McGlashan, T. H. (2002). Effects of development on olanzapine-associated adverse events. Journal of the American Academy of Child and Adolescent Psychiatry, 41(12), 1439-1446.
119. Wu, R. R., Zhao, J. P., Liu, Z. N., Zhai, J. G., Guo, X. F., Guo, W. B., et al. (2006). Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Psychopharmacology, 186(4), 572-578.
120. Wudarsky, M., Nicolson, R., Hamburger, S. D., Spechler, L., Gochman, P., Bedwell, J., et al. (1999). Elevated prolactin in pediatric patients on typical and atypical antipsychotics. Journal of Child and Adolescent Psychopharmacology, 9(4), 239-245.
121. Zarcone, J. R., Hellings, J. A., Crandall, K., Reese, R. M., Marquis, J., Fleming, K., et al. (2001). Effects of risperidone on aberrant behavior of persons with developmental disabilities: I. A double-blind crossover study using multiple measures. American Journal of Mental Retardation, 106(6), 525-538.
122. Zimmet, P., Alberti, K. G., Kaufman, F., Tajima, N., Silink, M., Arslanian, S., et al. (2007). The metabolic syndrome in children and adolescents an IDF consensus report. Pediatric Diabetes, 8(5), 299-306.